D. E. Shaw & Co., Inc. Ardelyx, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $156 Billion
- Q3 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Ardelyx, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 3,313,050 shares of ARDX stock, worth $19.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,313,050
Previous 2,458,666
34.75%
Holding current value
$19.4 Million
Previous $9.64 Million
89.77%
% of portfolio
0.01%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding ARDX
# of Institutions
244Shares Held
161MCall Options Held
697KPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA18.4MShares$108 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$103 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X013.8MShares$81.1 Million0.04% of portfolio
-
Macquarie Group LTD Australia, C310.5MShares$61.4 Million0.07% of portfolio
-
State Street Corp Boston, MA9.72MShares$57 Million0.0% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $908M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...